Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and...
VistaGen has a potentially pivotal Phase 3 trial of its Social Anxiety Disorder ("SAD") treatment PH94B upcoming. The trial is near-identical to its successful Phase 2 trial. The neurology specialist has 2 other candidates in development - 1 acquired from the same team that developed ...
VistaGen has had a tumultuous history, but recent trials have seen success. They may start phase 3 trials for PH94B in May. Dilution is a major risk. For further details see: VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin
SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and...
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depressio...
VistaGen Therapeutics (VTGN) has filed a prospectus for a mixed shelf offering of up to $250M.The filing does not necessarily indicate that a sale has begun, or will occur in the future.Shares up 3.5% after-hours. Yesterday's close was $2.35. For further details see: VistaGen ...
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anx...
Could These Penny Stocks Jump Next Month? February was definitely an interesting month for penny stocks . My guess is as March begins, investors hope that it will have a much better start than how this month ended. To categorize February, we have to consider all that has happened in...
Gainers: Immunome (IMNM) +120%.Greenland Technologies (GTEC) +119%.Liberty TripAdvisor (LTRPB) +60%.Motus GI Holdings (MOTS) +35%.Charah Solutions (CHRA) +35%.Avinger (AVGR) +34%.VistaGen Therapeutics (VTGN) +32%.U.S. Well Services (USWS) +28%.Ebang International (EBON) +28%.Os...
Gainers: Immunome (IMNM) +93%, Avinger (AVGR) +33%, Titan Pharmaceuticals (TTNP) +17%, GBS (GBS) +15%, VistaGen Therapeutics (VTGN) +15%.Losers: MEDNAX (MD) -23%, ReWalk Robotics (RWLK) -21%, Shineco (TYHT) -19%,&...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...